Anjana Edathil Kadangodan

The paper shows that cancer cells develop resistance to doxorubicin by accumulating mutations at Top2 cleavage sites, which prevent DNA damage and promote adaptation.

The paper shows that cancer cells generate non-random, high-frequency mutations during drug adaptation, enriched near transcription factor binding sites.